rs148434485
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_005373.3(MPL):c.127C>T(p.Arg43*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000167 in 1,614,058 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_005373.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- thrombocythemia 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen
- congenital amegakaryocytic thrombocytopeniaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics
- congenital amegakaryocytic thrombocytopenia 1Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- familial thrombocytosisInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary isolated aplastic anemiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MPL | NM_005373.3 | c.127C>T | p.Arg43* | stop_gained | Exon 2 of 12 | ENST00000372470.9 | NP_005364.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MPL | ENST00000372470.9 | c.127C>T | p.Arg43* | stop_gained | Exon 2 of 12 | 1 | NM_005373.3 | ENSP00000361548.3 | ||
| MPL | ENST00000413998.7 | c.106C>T | p.Arg36* | stop_gained | Exon 2 of 12 | 1 | ENSP00000414004.3 | |||
| MPL | ENST00000638732.1 | n.127C>T | non_coding_transcript_exon_variant | Exon 2 of 10 | 1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152170Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000318 AC: 8AN: 251424 AF XY: 0.0000294 show subpopulations
GnomAD4 exome AF: 0.0000150 AC: 22AN: 1461888Hom.: 0 Cov.: 33 AF XY: 0.0000151 AC XY: 11AN XY: 727246 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152170Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74344 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
MPL-related disorder Pathogenic:2
The MPL c.127C>T variant is predicted to result in premature protein termination (p.Arg43*). This variant has been reported in the homozygous and compound heterozygous states in multiple individuals with congenital amegakaryocytic thrombocytopenia (Table 4, Ballmaier et al. 2001. PubMed ID: 11133753; Table 1, Germeshausen et al. 2006. PubMed ID: 16470591; Savoia et al. 2007. PubMed ID: 17666371). This variant has also been observed in the heterozygous state in an individual with lung adenocarcinoma (Table S2, Huang et al. 2018. PubMed ID: 29625052). This variant is reported in 0.018% of alleles in individuals of African descent in gnomAD. Nonsense variants in MPL are expected to be pathogenic. This variant is interpreted as pathogenic. -
The MPL c.127C>T (p.Arg43Ter) variant is a stop-gained variant predicted to result in premature termination of the protein. The variant has been reported in three studies in which it is identified in a total of six individuals with congenital amegakaryocytic thrombocytopenia, all with a severe phenotype, in one individual in a compound heterozygous state and in five individuals in a homozygous state (Ballmaier et al. 2001; Germeshausen et al. 2006; Savoia et al. 2007). The p.Arg43Ter variant has not been reported in individuals with essential thrombocythemia. The p.Arg43Ter variant was absent from 50 controls and is reported at a frequency of 0.000041 in the total population of the Exome Aggregation Consortium. Savoia et al. (2007) demonstrated that platelet surface expression of other glycoproteins was normal in one individual carrying the variant but MPL expression was scarcely detectable. Serum TPO levels were elevated and in colony-forming unit assays, platelet c-MPL and bone marrow colonies were reduced. Based on the evidence and potential impact of stop-gained variants, the p.Arg43Ter variant is classified as pathogenic for MPL-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
Congenital amegakaryocytic thrombocytopenia 1 Pathogenic:2
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
PM2_Supporting+PVS1+PM3 -
Congenital amegakaryocytic thrombocytopenia Pathogenic:2
- -
Variant summary: MPL c.127C>T (p.Arg43X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 3.2e-05 in 251424 control chromosomes. c.127C>T has been reported in the literature in multiple individuals affected with Congenital Amegakaryocytic Thrombocytopenia (example, Ballmaier_2001, Germeshausen_2006). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:2
MPL: PVS1, PM2, PM3 -
- -
Primary myelofibrosis;C3275998:Thrombocythemia 2;C5882667:Congenital amegakaryocytic thrombocytopenia 1 Pathogenic:1
- -
Essential thrombocythemia;C1327915:Congenital amegakaryocytic thrombocytopenia Pathogenic:1
This sequence change creates a premature translational stop signal (p.Arg43*) in the MPL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MPL are known to be pathogenic (PMID: 8073287, 11133753). This variant is present in population databases (rs148434485, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with congenital amegakaryocytic thrombocytopenia (PMID: 11133753, 16470591). ClinVar contains an entry for this variant (Variation ID: 371574). For these reasons, this variant has been classified as Pathogenic. -
Thrombocythemia 2 Pathogenic:1
The MPL c.127C>T (p.Arg43Ter) change is a nonsense variant that is predicted to cause premature protein truncation and loss of normal protein function. Loss-of-function variants in MPL are known to be pathogenic (PMID: 8073287, 11133753). Colony assays have shown a notable decrease in the total number of colony-forming cells from congenital amegakaryocytic thrombocytopenia I patients carrying this variant and other nonsense mutations compared to those from healthy donors (PMID: 16470591). In addition, an expression analysis conducted on hematopoietic progenitor cells revealed a lack of CD110 expression in patients harboring this variant, as well as in individuals with other nonsense or frameshift mutations and mutations predicted to result in complete splice site loss (PMID: 32703794). This variant has been identified as a homozygous mutation in multiple individuals with congenital amegakaryocytic thrombocytopenia (PMID: 11133753, 16470591, 17666371, 18090929). To our knowledge, this variant has not been reported in individuals with thrombocythemia. This variant has a maximum subpopulation frequency of 0.018% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). In summary, this variant meets criteria to be classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at